Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
General17 hours agoVictorian school teacher charged with soliciting child abuse material
-
General8 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Business23 hours agoWhy Telix shares could rocket 60%+
-
Noosa News23 hours agoBrisbane news LIVE updates: University gains Olympic scholarships